Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07015437 · ClinicalTrials.gov registry record · Phase 2
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
A Phase 2 study of Healthy Subjects, sponsored by Cerus Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 2
- Study locations
NCT07015437: Recruiting Phase 2 study of Healthy Subjects, sponsored by Cerus Corporation.
NCT07015437 is a Phase 2 study of Healthy Subjects that is actively recruiting participants, run by Cerus Corporation. The registered enrollment target is 70 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07015437, a Phase 2 study of Healthy Subjects, is actively recruiting participants, sponsored by Cerus Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this trial is to assess the post-infusion viability of INTERCEPT RBCs by measuring the 24-hour post-infusion recovery and lifespan of autologous RBCs prepared with the INTERCEPT Blood System for RBC with AS-1 after 35 days post collection storage in comparison to untreated AS-1 RBCs stored for 35 days.
Primary Outcome
The 24-hour recovery will be calculated using the subject's blood volume derived from infusion of 99mTc-labeled fresh RBCs.
Conditions Studied
Interventions
- DEVICE INTERCEPT Blood System for RBCs
- OTHER Infusion of autologous radiolabeled RBCs
Study Locations (2)
Ohio
- Hoxworth Blood Center - Cincinnati
Virginia
- American Red Cross Research Laboratory - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2026-10-15 |
| Phase | Phase 2 |
What NCT07015437 shows while recruiting
NCT07015437 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which INTERCEPT Blood System for RBCs is the first listed.
NCT07015437 reports a single indexed study location in Ohio, Virginia.
Frequently Asked Questions
What is clinical trial NCT07015437 about?
NCT07015437 is a clinical study titled "A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1". The objective of this trial is to assess the post-infusion viability of INTERCEPT RBCs by measuring the 24-hour post-infusion recovery and lifespan of autologous RBCs prepared with the INTERCEPT Blood System for RBC with AS-1 after 35 days post collection storage in comparison to untreated AS-1 RBCs...
What is the current status of trial NCT07015437?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-09-19. Estimated completion is 2026-10-15.
What conditions does trial NCT07015437 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT07015437?
The interventions under investigation include: INTERCEPT Blood System for RBCs (DEVICE), Infusion of autologous radiolabeled RBCs (OTHER).
Who is sponsoring clinical trial NCT07015437?
This trial is sponsored by Cerus Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07015437 being conducted?
This trial has 2 study locations across Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07015437's enrollment target sits among peer trials
70 19th of 69 higher than 51 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
COMPLETED · Phase 2
-
Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth
COMPLETED · Phase 2
-
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
RECRUITING
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
Radiocaine Safety Study In Healthy Human Subjects
RECRUITING · Early Phase 1
-
Optimizing Ultrasound-induced Anti-inflammation in Human Subjects
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI